Prof. Dr Hemant Malhotra is the Director of Oncology Services at Sri Ram Cancer Centre and Professor & Head of the Department of Medical Oncology at Mahatma Gandhi Medical College Hospital (MGMCH), Jaipur. With over three decades of experience in oncology, he has been instrumental in advancing cancer care in North India. Prior to his current role at MGMCH, he was Professor and Head of the Department of Medicine and the Division of Medical Oncology at the Birla Cancer Centre, SMS Medical College, Jaipur.

Under his leadership, the Sri Ram Cancer Centre at MGMCH has developed into one of North India’s leading comprehensive cancer centres. It houses an active Stem Cell Transplantation Unit and offers Rajasthan’s first DM (super-specialty) course in Medical Oncology, recognised by the National Medical Commission (NMC). MGMCH is a 1,400-bed tertiary care teaching hospital and the largest private-sector healthcare institution in the region.

Dr Malhotra graduated from SMS Medical College, where he topped his class. He pursued advanced oncology training through fellowships at Tata Memorial Cancer Centre in Mumbai (1989-1991), Cornell Medical Centre in New York, and Memorial Sloan Kettering Cancer Centre in New York. Upon returning to India, he established Rajasthan’s first Medical Oncology division at SMS Medical College in 1991 and later set up the state’s first Bone Marrow Transplantation Unit. His team successfully performed Rajasthan’s first autologous bone marrow transplant.

A dedicated educator, Dr Malhotra has trained numerous oncologists, many of whom now lead their own departments across India. He is highly regarded both nationally and internationally. From 2006 to 2008, he represented India, Pakistan, and Bangladesh at the European Society for Medical Oncology (ESMO) and remains ESMO board-certified in medical oncology. He is also an active member of the ESMO Public Policy Committee.

Dr Malhotra plays a key role in oncology research, policymaking, and clinical guideline development. He serves as an advisor, consultant, and committee member for various Government of India bodies, including the Indian Council of Medical Research (ICMR), where he leads the guideline development committee for multiple myeloma. He is a member of the Subject Expert Committee (SEC) on Haematology & Oncology under the Drug Controller General of India and has previously served on the National Oncology Serious Adverse Events (SAE) Committee. Additionally, he has been a consultant to the World Health Organization (WHO) for biosimilar oncology guidelines.

With over 300 national and international publications and presentations to his credit, Dr Malhotra is a distinguished contributor to medical literature. He is the lead author of the Chronic Leukaemia chapter in the Oxford Textbook of Oncology. He currently serves as President of the Immuno-Oncology Society of India (I-OSI) and the Teen & Young Adult Cancer (TYACAN) Foundation. He is the Immediate Past President of the Indian Society of Medical & Paediatric Oncology (ISMPO) and the President-Elect of the Indian Society of Oncology (ISO). He is also a founding member and Head of the Haematological Cancers Committee of the Indian Cooperative Oncology Network (ICON).

A strong advocate for clinical research, Dr Malhotra has led over 50 investigator-initiated and industry-sponsored clinical trials, particularly in chronic myeloid leukaemia (CML). His expertise in research ethics is reflected in his long-standing role as Joint Secretary of the Ethics Committee at SMS Medical College, where he played a key role in drafting its Standard Operating Procedures.

Dr Malhotra has received multiple national and international honours. In 2018, he was awarded the International Chronic Myeloid Leukaemia Prize in Miami, USA, for his contributions to CML research in emerging regions. In 2019, he was the only physician from India invited to chair and speak at the 62nd Annual Meeting of the American Society of Haematology (ASH) in Orlando, USA. He is also a member of the European LeukaemiaNet (ELN) guideline committee for CML.

His recent engagements include invited lectures at the Annual Congress of the European Haematology Association (EHA) in Madrid, Spain (June 2024) and the European Society for Medical Oncology (ESMO) Asia Congress in Singapore (December 2024).

Through his extensive contributions to patient care, research, education, and policymaking, Dr Malhotra continues to shape the future of oncology in India and beyond.